GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for GTB-3650.

GT Biopharma, Inc. has reached a significant milestone in its mission to develop cutting-edge therapies for cancer patients. CD33+ Leukemia is a subtype of acute myeloid leukemia (AML) that presents a particularly challenging treatment landscape. The submission of the IND application for GTB-3650 marks a crucial step towards providing a novel treatment option for patients battling this aggressive form of leukemia.

The TriKE® platform developed by GT Biopharma harnesses the power of natural killer (NK) cells to target cancer cells with precision. By engaging the body’s own immune system in the fight against cancer, GTB-3650 offers a promising new approach to treating CD33+ Leukemia. The IND submission with the FDA demonstrates the company’s commitment to advancing this potentially life-saving therapy through rigorous clinical development.

GTB-3650 has shown promising results in preclinical studies, with strong evidence of its ability to effectively target and eliminate CD33+ leukemia cells. By moving forward with the IND submission, GT Biopharma is paving the way for future clinical trials that will evaluate the safety and efficacy of GTB-3650 in patients with this challenging disease.

CD33 is a cell surface antigen that is commonly expressed on leukemia cells, making it an attractive target for immunotherapy. GTB-3650 is designed to specifically target CD33-expressing cells while sparing normal healthy cells, reducing the risk of off-target effects commonly associated with traditional chemotherapy. This targeted approach holds great promise for improving patient outcomes and reducing the burden of side effects associated with current treatment options.

How will this affect me?

As a patient with CD33+ Leukemia, the IND submission for GTB-3650 offers hope for a new treatment option that could potentially improve outcomes and quality of life. By targeting cancer cells with precision and harnessing the power of the immune system, GTB-3650 represents a promising advancement in the field of immuno-oncology.

How will this affect the world?

The submission of an IND application for GTB-3650 represents a significant advancement in the field of cancer research and treatment. If successful, this novel therapy has the potential to revolutionize the treatment landscape for CD33+ Leukemia and other types of cancer, offering new hope to patients worldwide. By developing innovative therapies like GTB-3650, GT Biopharma is driving forward the fight against cancer and paving the way for a future where more effective and targeted treatments are available to those in need.

Conclusion

GT Biopharma’s announcement of the IND submission for GTB-3650 is a major milestone in the development of innovative therapies for cancer patients. This groundbreaking treatment has the potential to transform the way we approach the treatment of CD33+ Leukemia and other types of cancer, offering new hope to patients and their families. By leveraging the power of the immune system and targeting cancer cells with precision, GTB-3650 represents a promising advancement in the field of immuno-oncology that has the potential to make a significant impact on the lives of patients worldwide.